Factors Associated with Infection or Colonization of Vancomycin-Resistant Enterococci (VRE) among Hospitalized Patients in Chonburi Hospital
Keywords:
VRE, Vancomycin Resistant Enterococci, factors, hospitalized patientsAbstract
This matched case-control study aims were to describe the epidemiology of vancomycin-resistant enterococci (VRE), including both infections and colonization, and to identify factors associated with infection or colonization of VRE among hospitalized patients. The study was conducted at Chonburi Hospital between January 1, 2011 and December 31, 2018. The cases were 75 patients colonized or infected with VRE, and the controls were 150 patients with vancomycin-sensitive enterococci isolates. Both groups were matched by sex, age ±5 years, and same type of specimens in the same month. Data were collected retrospectively from the hospital’s electronic medical record database and culture test results. Conditional logistic regression was used to identify risk factors for VRE infection or colonization. Odds ratio (OR) and 95% confidence intervals (CI) were calculated. A p-value of less than 0.05 (<0.05) was considered to indicate statistical significance.
The results revealed that patients with indwelling medical devices (e.g. endotracheal tube, NG tube) were found in both groups. Patients in both case and control groups had been prescribed antibiotics within one month (94.7% and 74%, respectively). E. faecium isolates were more resistant to vancomycin than E. faecalis (96% and 4% respectively). Factors associated with VRE infection or colonization included previous administration of vancomycin (OR adj = 14.36; 95% CI, 3.81-54.03), cephalosporins (OR adj = 3.49; 95% CI, 1.49-8.14) and colistin (OR adj = 7.84; 95% CI, 2.23-27.69) within one month during the period of hospitalization. The findings highlight the need for promoting the rational use of antibiotics and strengthening of infection control procedures and practices to prevent the spread of VRE in the hospital.
References
Bonten MJM, Willems R, Weinstein RA. Vanco-mycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis 2001;1(5):314–25.
Leclercq R, Derlot E, Duval J, Courvalin P. Plas-mid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319(3):157–61.
Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections summary of data reported to the Na-tional Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol 2013;34(1):1–14.
Centers for Disease Control and Prevention. Noso-comial enterococci resistant to vancomycin--United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993;42(30):597.
กรมวิทยาศาสตร์การแพทย์. “60 ร.พ. เครือข่ายร่วมเฝ้าระวังแบคทีเรียดื้อยา ด้วยโปรแกรมฮูเน็ต (WHONET).” จดหมายข่าว 2557;28(Suppl6):4.
Sohn KM, Peck KR, Joo E-J, Ha YE, Kang C-I, Chung DR, et al. Duration of colonization and risk factors for prolonged carriage of vancomycin-resistant enterococci after discharge from the hospital. Int J Infect Dis 2013;17(4):e240–6.
Schlesselman JJ. Case-control studies: design, con-duct, analysis. New York: Oxford University Press; 1982.
Tornieporth NG, Roberts RB, John J, Hafner A, Riley LW. Risk factors associated with vancomycin-resist-ant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996;23(4):767–72.
Clinical and Laboratory Standards Institute. Perfor-mance Standards for Antimicrobial Susceptibility Testing. 29th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2019.
Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013 [Internet]. Georgia: Centres for Disease Control and Prevention, US Department of Health and Human Services; 2013 [cited 2019 Jul 14]. Available from: https://www.cdc.gov/drugre-sistance/pdf/ar-threats-2013-508.pdf
Garbutt JM, Ventrapragada M, Litten-berg B, Mundy LM. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis 2000;30(3):466–72.
Faron ML, Ledeboer NA, Buchan BW. Resistance mechanisms, epidemiology, and approaches to screening for vancomycin-resistant enterococ-cus in the health care setting. J Clin Microbiol 2016;54(10):2436–47.
Fridkin SK, Edwards JR, Courval JM, Hill H, Tenover FC, Lawton R, et al. The effect of van-comycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 US adult intensive care units. Ann Intern Med 2001;135(3):175–83.
Willems RJL, Van Schaik W. Transition of Enterococ-cus faecium from commensal organism to nosocomial pathogen. Future Microbiol 2009;4(9):1125–35.
Hidron AI, Edwards JR, Patel J, Horan TC, Siev-ert DM, Pollock DA, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol 2008;29(11):996–1011.
Chongthaleong A. Vancomycin-resistant enterococci in King Chulalongkorn Memorial Hospital: a 5-year study. J Med Assoc Thai 2003;86(2):S224–9.
Frieden TR, Munsiff SS, Williams G, Faur Y, Kreiswirth B, Low DE, et al. Emergence of vanco-mycin-resistant enterococci in New York City. Lancet 1993;342(8863):76–9.
Jiang H-L, Zhou Z, Wang L-S, Fang Y, Li Y-H, Chu C-I. The risk factors, costs, and survival analysis of invasive VRE infections at a medical center in eastern Taiwan. Int J Infect Dis 2017;54:18–24.
Linden PK, Pasculle AW, Manez R, Kramer DJ, Fung JJ, Pinna AD, et al. Differences in outcomes for pa-tients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996;22(4):663–70.
Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999;20(5):318–23.
Padiglione AA, Wolfe R, Grabsch EA, Olden D, Pearson S, Franklin C, et al. Risk factors for new detection of vancomycin-resistant enterococci in acute-care hospitals that employ strict infection control procedures. Antimicrob Agents Chemother 2003;47(8):2492–8.
Montecalvo MA, Jarvis WR, Uman J, Shay DK, Petrullo C, Rodney K, et al. Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Ann Intern Med 1999;131(4):269–72.
Shorman M, Al-Tawfiq JA. Risk factors associated with vancomycin-resistant enterococcus in inten-sive care unit settings in Saudi Arabia. Interdiscip Perspect Infect Dis [Internet]. 2013 [cited 2019 Jul 10];2013:1–4. Available from: http://www.hindawi.com/journals/ipid/2013/369674/
Baden LR, Thiemke W, Skolnik A, Chambers R, Strymish J, Gold HS, et al. Prolonged coloni-zation with vancomycin-resistant Enterococcus faecium in long-term care patients and the significance of “clearance.” Clin Infect Dis 2001;33(10):1654–60.
Workneh MH, Bjune GA, Yimer SA, MH W, GA B, SA Y. Prevalence and associated factors of tuberculosis and diabetes mellitus comorbidity: a systematic review. Wilkinson KA, editor. PLoS One [Internet]. 2017 Apr 21 [cited 2019 Jul 11];12(4):e0175925. Available from: http://dx.plos.org/10.1371/journal.pone.0175925
Sakka V, Tsiodras S, Galani L, Antoniadou A, Souli M, Galani I, et al. Risk-factors and predictors of mortality in patients colonised with vancomycin-re-sistant enterococci. Clin Microbiol Infect [Internet].2008 Jan [cited 2019 Jul 11];14(1):14–21. Availa-ble from: https://linkinghub.elsevier.com/retrieve/pii/S1198743X14606406
McNeil SA, Malani PN, Chenoweth CE, Fontana RJ, Magee JC, Punch JD, et al. Vancomycin-re-sistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis 2006;42(2):195–203.
Carmeli Y, Eliopoulos GM, Samore MH. Antece-dent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis [Internet]. 2002 Aug [cited 2019 Jul 10];8(8):802–7. Available from: http://wwwnc.cdc.gov/eid/article/8/8/01-0418_article.htm
Harbarth S, Cosgrove S, Carmeli Y. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimi-crob Agents Chemother 2002;46(6):1619–28.
Karki S, Houston L, Land G, Bass P, Kehoe R, Borrell S, et al. Prevalence and risk factors for VRE colonisation in a tertiary hospital in Melbourne, Australia: a cross sectional study. Antimicrob Resist Infect Control 2012;1(1):31.
Fisher K, Phillips C. The mechanism of action of a citrus oil blend against Enterococcus faecium and Enterococcus faecalis. J Appl Microbiol 2009;106(4):1343–9.
Ahmed MO, Baptiste KE. Vancomycin-resistant enterococci: a review of antimicrobial resistance mechanisms and perspectives of human and animal health. Microb Drug Resist 2018;24(5):590–606.
Shankar N, Baghdayan AS, Gilmore MS. Mod-ulation of virulence within a pathogenicity island in vancomycin-resistant Enterococcus faecalis. Nature [internet]. 2002 Jun [cited 2019 Jul 14];417(6890):746–50. Available from: http://www.nature.com/articles/nature00802
Bonten MJM, Hayden MK, Nathan C, van Voorhis J, Matushek M, Slaughter S, et al. Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci. Lancet 1996;348(9042):1615–9.
Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000;343(26):1925–32.
Downloads
Published
Versions
- 2026-02-13 (2)
- 2020-09-02 (1)
Issue
Section
License
Copyright (c) 2020 Chonburi Hospital Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพิ์เป็นลิขสิทธิ์ของวารสารโรงพยาบาลชลบุรี